Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Anvumetostat in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT06593522 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT06593522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06593522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Anvumetostat in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 26, 2024
Completion date
November 30, 2026
Enrollment
61 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

mtap-deleted nsclc